Dashboard
Weak Long Term Fundamental Strength with a -18.16% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 5.93% signifying low profitability per unit of shareholders funds
The company has declared Negative results for the last 10 consecutive quarters
Stock DNA
Pharmaceuticals & Biotechnology
INR 801 Cr (Micro Cap)
384.00
40
0.00%
0.43
0.71%
2.73
Total Returns (Price + Dividend) 
Latest dividend: 0.1666815144766147 per share ex-dividend date: Sep-19-2019
Risk Adjusted Returns v/s 
Returns Beta
News

Zim Laboratories Ltd is Rated Sell by MarketsMOJO
Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read More
Zim Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite a recent day decline of 1.73%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of price attractiveness relative to its historical and peer benchmarks.
Read More
Zim Laboratories Ltd is Rated Sell by MarketsMOJO
Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 November 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11-Nov-2026 | Source : BSETranscript of Q2 & H1FY27 Earnings Conference Call
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
05-Nov-2026 | Source : BSEPlease find enclosed the disclosure pertaining to the audio recording of Q2 & H1 FY27 Earnings Conference Call.
Announcement under Regulation 30 (LODR)-Newspaper Publication
05-Nov-2026 | Source : BSEPlease find enclosed the Newspaper Publication of financial results for the Quarter & Half yearly ended 30th September 2026.
Corporate Actions 
No Upcoming Board Meetings
Zim Laboratories Ltd has declared 5% dividend, ex-date: 19 Sep 19
No Splits history available
Zim Laboratories Ltd has announced 2:1 bonus issue, ex-date: 22 Dec 22
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 1 Schemes (1.18%)
Held by 3 FIIs (0.17%)
Anwar Siraj Daud (25.03%)
Elimath Advisors Private Limited (10.41%)
31.03%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 18.87% vs -3.72% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -388.10% vs -117.65% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -7.76% vs 13.51% in Sep 2024
Growth in half year ended Sep 2025 is -170.12% vs -25.11% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -0.43% vs 8.31% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -71.15% vs -20.52% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -1.22% vs 3.16% in Mar 2025
YoY Growth in year ended Mar 2026 is -52.01% vs -29.45% in Mar 2025